The story of Sildenafil presents a complex picture for those considering investment. While the initial release generated substantial returns, the end of its exclusive rights opened the floodgates to off-brand versions, https://wise-social.com/story7207971/the-copyright-and-big-pharma-a-volatile-opportunity